$INSM

Adsett Roger sold $242K of INSM

Adsett Roger (Chief Operating Officer) sold 2,370 shares of INSMED Inc (INSM) at $102.27 ($0.24M total) on 2026-06-03.

Original reporting
SEC EDGAR · Adsett Roger
Published Jun 5, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INSM
Bearish
medium confidence
Mentioned
$INSM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

Traders may treat it as a mild sentiment input, but without earnings, trial, or deal updates it should not drive a standalone thesis.

02

Market read

A single officer sale disclosed after execution; potential short-term sentiment drag but no fundamental catalyst provided.

03

What to watch

No context on total insider holdings, prior sales cadence, or whether other insiders/large holders acted around the same time.

Relevance 6/10Novelty 6/10Timing: Filed June 5; sale executed June 3.

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the COO.

Company-level read

Ticker impact

$INSMBearishMedium confidence
Context

INSMED COO Adsett Roger sold 2,370 shares in an open-market transaction disclosed via SEC Form 4 on June 3.

Expected impact

Likely limited near-term impact; could add slight selling pressure or raise caution among short-term traders.

Evidence & confidence

The filing is a disclosed officer sale, not a planned 10b5-1 plan, but the article lacks size vs. float context or any accompanying company-specific news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan doesn’t necessarily imply bearish fundamentals.

Key entities

  • INSMED Inc

    Company whose insider transaction was disclosed (INSM).

  • Adsett Roger

    Chief Operating Officer who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.